[{"id":"86dcbaa4-a0f7-4722-b301-afe751349fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07479485","created_at":"2026-03-28T01:39:14.150Z","updated_at":"2026-03-28T01:39:14.150Z","phase":"Phase 1/2","brief_title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","source_id_and_acronym":"NCT07479485","lead_sponsor":"Lepu Biopharma Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2026-03-18"},{"id":"95af4e00-bb4a-434c-a34b-1b5eb891c198","acronym":"","url":"https://clinicaltrials.gov/study/NCT04550481","created_at":"2025-08-02T14:05:48.713Z","updated_at":"2025-08-02T14:05:48.713Z","phase":"Phase 2","brief_title":"Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study","source_id_and_acronym":"NCT04550481","lead_sponsor":"Northwestern University","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 05/11/2021","start_date":" 05/11/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-07-29"},{"id":"62872999-7328-472a-bcf9-8d2b97b69282","acronym":"","url":"https://clinicaltrials.gov/study/NCT07053202","created_at":"2025-07-12T13:55:24.826Z","updated_at":"2025-07-12T13:55:24.826Z","phase":"","brief_title":"TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma","source_id_and_acronym":"NCT07053202","lead_sponsor":"The First Hospital of Hebei Medical University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab)"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 11/01/2022","primary_completion_date":" 11/01/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2025-07-08"},{"id":"ddd7f583-bad9-403a-9835-38c48d3a337c","acronym":"DARTS","url":"https://clinicaltrials.gov/study/NCT07027436","created_at":"2025-06-21T13:17:48.762Z","updated_at":"2025-06-21T13:17:48.762Z","phase":"Phase 3","brief_title":"Radiation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellular Carcinoma.","source_id_and_acronym":"NCT07027436 - DARTS","lead_sponsor":"Hamilton Health Sciences Corporation","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/07/2025","start_date":" 07/07/2025","primary_txt":" Primary completion: 10/12/2027","primary_completion_date":" 10/12/2027","study_txt":" Completion: 10/10/2028","study_completion_date":" 10/10/2028","last_update_posted":"2025-06-18"},{"id":"435f6562-3a9d-4c61-986e-62e2329bff47","acronym":"CCGLC-017","url":"https://clinicaltrials.gov/study/NCT06954116","created_at":"2025-06-14T13:51:50.396Z","updated_at":"2025-06-14T13:51:50.396Z","phase":"Phase 2","brief_title":"Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With High Risk of Recurrence","source_id_and_acronym":"NCT06954116 - CCGLC-017","lead_sponsor":"Tongji Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/01/2025","start_date":" 08/01/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2025-06-13"},{"id":"2304e211-cb24-49e4-804c-c1f372c07411","acronym":"ARTEMIDE-HCC01","url":"https://clinicaltrials.gov/study/NCT06921785","created_at":"2025-06-07T14:44:45.235Z","updated_at":"2025-06-07T14:44:45.235Z","phase":"Phase 3","brief_title":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","source_id_and_acronym":"NCT06921785 - ARTEMIDE-HCC01","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Imjudo (tremelimumab-actl) • rilvegostomig (AZD2936)"],"overall_status":"Recruiting","enrollment":" Enrollment 1220","initiation":"Initiation: 05/06/2025","start_date":" 05/06/2025","primary_txt":" Primary completion: 03/16/2029","primary_completion_date":" 03/16/2029","study_txt":" Completion: 03/15/2030","study_completion_date":" 03/15/2030","last_update_posted":"2025-05-31"},{"id":"f717121f-6913-41a9-bfde-2932abad4e9e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06891742","created_at":"2025-06-28T16:10:54.772Z","updated_at":"2025-06-28T16:10:54.772Z","phase":"Phase 1","brief_title":"Phase I Study of OriC902 in Treatment of Advanced HCC","source_id_and_acronym":"NCT06891742","lead_sponsor":"Peking University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/24/2025","start_date":" 02/24/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 03/31/2028","study_completion_date":" 03/31/2028","last_update_posted":"2025-03-24"},{"id":"66bf38b6-9dea-4df8-a339-ddaabf2340cf","acronym":"ATHENA","url":"https://clinicaltrials.gov/study/NCT04856046","created_at":"2021-04-22T20:53:47.939Z","updated_at":"2025-02-25T12:28:04.369Z","phase":"","brief_title":"Detection of Plasma DNA Methylation in Peripheral Blood from Patients with Resectable Liver Cancer","source_id_and_acronym":"NCT04856046 - ATHENA","lead_sponsor":"Mayo Clinic","biomarkers":" AFP","pipe":"","alterations":" ","tags":["AFP"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 11/06/2021","start_date":" 11/06/2021","primary_txt":" Primary completion: 05/15/2026","primary_completion_date":" 05/15/2026","study_txt":" Completion: 05/15/2027","study_completion_date":" 05/15/2027","last_update_posted":"2025-02-24"},{"id":"8928481a-724a-435c-8656-726fa0e4aab3","acronym":"GLYCAR","url":"https://clinicaltrials.gov/study/NCT02905188","created_at":"2021-03-12T22:55:55.778Z","updated_at":"2025-02-25T12:26:31.981Z","phase":"Phase 1","brief_title":"Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)","source_id_and_acronym":"NCT02905188 - GLYCAR","lead_sponsor":"Baylor College of Medicine","biomarkers":" GPC3","pipe":" | ","alterations":" GPC3 positive","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • GLYCAR T cells • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 11/17/2021","primary_completion_date":" 11/17/2021","study_txt":" Completion: 01/06/2023","study_completion_date":" 01/06/2023","last_update_posted":"2025-02-24"},{"id":"b49f18b2-c9ae-436d-b40d-5082e9ce8d13","acronym":"","url":"https://clinicaltrials.gov/study/NCT06842563","created_at":"2025-02-25T13:29:03.294Z","updated_at":"2025-02-25T13:29:03.294Z","phase":"","brief_title":"Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial","source_id_and_acronym":"NCT06842563","lead_sponsor":"Singlera Genomics Inc.","biomarkers":" DAB2IP","pipe":"","alterations":" ","tags":["DAB2IP"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 900","initiation":"Initiation: 02/20/2025","start_date":" 02/20/2025","primary_txt":" Primary completion: 11/20/2025","primary_completion_date":" 11/20/2025","study_txt":" Completion: 12/20/2025","study_completion_date":" 12/20/2025","last_update_posted":"2025-02-24"},{"id":"ec39bba5-c725-4310-a7b9-db843f8fcd99","acronym":"AdvanTIG-206","url":"https://clinicaltrials.gov/study/NCT04948697","created_at":"2021-07-02T12:52:38.466Z","updated_at":"2025-02-25T12:28:13.406Z","phase":"Phase 2","brief_title":"A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC","source_id_and_acronym":"NCT04948697 - AdvanTIG-206","lead_sponsor":"BeiGene","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • Avzivi (bevacizumab-tnjn) • ociperlimab (BGB-A1217)"],"overall_status":"Completed","enrollment":" Enrollment 94","initiation":"Initiation: 08/20/2021","start_date":" 08/20/2021","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 02/01/2024","study_completion_date":" 02/01/2024","last_update_posted":"2025-02-24"},{"id":"d0e8c003-1353-4bf0-ae65-13236586de27","acronym":"AIM-NIVO","url":"https://clinicaltrials.gov/study/NCT03816345","created_at":"2021-01-18T18:51:20.043Z","updated_at":"2025-02-25T13:39:45.299Z","phase":"Phase 1","brief_title":"Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer","source_id_and_acronym":"NCT03816345 - AIM-NIVO","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • IL2","pipe":"","alterations":" ","tags":["MSI • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 07/16/2019","start_date":" 07/16/2019","primary_txt":" Primary completion: 08/31/2026","primary_completion_date":" 08/31/2026","study_txt":" Completion: 08/31/2026","study_completion_date":" 08/31/2026","last_update_posted":"2025-02-21"},{"id":"e9e77af0-89f1-42d4-a03f-cc0813b452ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT06027086","created_at":"2023-09-07T16:09:42.798Z","updated_at":"2025-02-25T13:41:42.827Z","phase":"Phase 1/2","brief_title":"DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)","source_id_and_acronym":"NCT06027086","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" DNAJB1 • PRKACA","pipe":" | ","alterations":" DNAJB1-PRKACA fusion","tags":["DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e DNAJB1-PRKACA fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • sirpiglenastat (DRP-104)"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 02/12/2024","start_date":" 02/12/2024","primary_txt":" Primary completion: 09/01/2028","primary_completion_date":" 09/01/2028","study_txt":" Completion: 09/01/2033","study_completion_date":" 09/01/2033","last_update_posted":"2025-02-21"},{"id":"5b604fcd-b187-4ac2-8cb5-8e6c3fc1616c","acronym":"CheckMate 8KX","url":"https://clinicaltrials.gov/study/NCT03656718","created_at":"2021-01-18T17:56:53.970Z","updated_at":"2025-02-25T13:52:39.029Z","phase":"Phase 1/2","brief_title":"A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)","source_id_and_acronym":"NCT03656718 - CheckMate 8KX","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Opdivo Qvantig (nivolumab and hyaluronidase-nvhy)"],"overall_status":"Completed","enrollment":" Enrollment 139","initiation":"Initiation: 10/29/2018","start_date":" 10/29/2018","primary_txt":" Primary completion: 09/07/2022","primary_completion_date":" 09/07/2022","study_txt":" Completion: 09/12/2024","study_completion_date":" 09/12/2024","last_update_posted":"2025-02-20"},{"id":"102a276a-2e7a-4a7f-a75b-c71813873058","acronym":"JS001-027-III-HCC","url":"https://clinicaltrials.gov/study/NCT04523493","created_at":"2021-01-18T21:40:02.000Z","updated_at":"2025-02-25T14:02:00.920Z","phase":"Phase 3","brief_title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","source_id_and_acronym":"NCT04523493 - JS001-027-III-HCC","lead_sponsor":"Shanghai Junshi Bioscience Co., Ltd.","biomarkers":" PD-L1 • TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1 • TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib) • Loqtorzi (toripalimab-tpzi)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 530","initiation":"Initiation: 06/29/2020","start_date":" 06/29/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-19"},{"id":"6a10d540-3227-4566-8606-34570d8b161e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04580485","created_at":"2021-02-24T11:03:20.215Z","updated_at":"2025-02-25T14:07:56.143Z","phase":"Phase 1","brief_title":"INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04580485","lead_sponsor":"Incyte Corporation","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr) • INCB106385"],"overall_status":"Completed","enrollment":" Enrollment 54","initiation":"Initiation: 02/03/2021","start_date":" 02/03/2021","primary_txt":" Primary completion: 01/22/2024","primary_completion_date":" 01/22/2024","study_txt":" Completion: 01/22/2024","study_completion_date":" 01/22/2024","last_update_posted":"2025-02-18"},{"id":"89ce58f7-0046-45a6-9589-68bba343777d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05249426","created_at":"2024-03-27T13:37:18.528Z","updated_at":"2025-02-25T14:16:43.633Z","phase":"Phase 1","brief_title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","source_id_and_acronym":"NCT05249426","lead_sponsor":"Boehringer Ingelheim","biomarkers":" SIRPA","pipe":"","alterations":" ","tags":["SIRPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Tecentriq (atezolizumab) • paclitaxel • docetaxel • capecitabine • ezabenlimab (BI 754091) • BI 765063 • BI 836880"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 04/12/2022","start_date":" 04/12/2022","primary_txt":" Primary completion: 07/16/2024","primary_completion_date":" 07/16/2024","study_txt":" Completion: 08/02/2025","study_completion_date":" 08/02/2025","last_update_posted":"2025-02-18"},{"id":"f183e140-987d-476d-a6b5-4df9e4ffb873","acronym":"TCR-T","url":"https://clinicaltrials.gov/study/NCT05417932","created_at":"2022-06-14T22:56:30.934Z","updated_at":"2025-02-25T14:08:55.469Z","phase":"Phase 1/2","brief_title":"A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma","source_id_and_acronym":"NCT05417932 - TCR-T","lead_sponsor":"SCG Cell Therapy Pte. Ltd.","biomarkers":" STMN2","pipe":"","alterations":" ","tags":["STMN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCG101"],"overall_status":"Recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-02-18"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"59d4a003-e862-4682-ad7b-ffa3cb7e3e25","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190174","created_at":"2021-01-18T15:43:45.733Z","updated_at":"2025-02-25T14:15:01.560Z","phase":"Phase 1/2","brief_title":"Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers","source_id_and_acronym":"NCT03190174","lead_sponsor":"Sarcoma Oncology Research Center, LLC","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2017","start_date":" 08/24/2017","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/02/2021","study_completion_date":" 12/02/2021","last_update_posted":"2025-02-17"},{"id":"0b525e9d-4ff9-4d49-a886-decd1a174c57","acronym":"","url":"https://clinicaltrials.gov/study/NCT04643574","created_at":"2021-01-19T20:39:09.813Z","updated_at":"2025-02-25T14:40:41.852Z","phase":"Phase 1","brief_title":"NeoTIL in Advanced Solid Tumors","source_id_and_acronym":"NCT04643574","lead_sponsor":"Centre Hospitalier Universitaire Vaudois","biomarkers":" TNFA • IL2","pipe":"","alterations":" ","tags":["TNFA • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 03/09/2021","start_date":" 03/09/2021","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2025-02-14"},{"id":"208e94c5-11e1-4e2c-881a-18ba9d9acb7c","acronym":"","url":"https://clinicaltrials.gov/study/NCT06620302","created_at":"2025-02-25T15:15:08.184Z","updated_at":"2025-02-25T15:15:08.184Z","phase":"Phase 1/2","brief_title":"Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma","source_id_and_acronym":"NCT06620302","lead_sponsor":"Children's Oncology Group","biomarkers":" BCL2 • DNAJB1 • PRKACA","pipe":"","alterations":" ","tags":["BCL2 • DNAJB1 • PRKACA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • DT2216"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 81","initiation":"Initiation: 03/20/2025","start_date":" 03/20/2025","primary_txt":" Primary completion: 12/30/2031","primary_completion_date":" 12/30/2031","study_txt":" Completion: 12/30/2031","study_completion_date":" 12/30/2031","last_update_posted":"2025-02-13"},{"id":"6645a7c8-abbe-46a7-be97-ec48de55bd51","acronym":"","url":"https://clinicaltrials.gov/study/NCT02070549","created_at":"2021-01-18T09:32:22.387Z","updated_at":"2025-02-25T15:10:06.793Z","phase":"Phase 1","brief_title":"Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction","source_id_and_acronym":"NCT02070549","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • omipalisib (GSK2126458)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 03/10/2014","start_date":" 03/10/2014","primary_txt":" Primary completion: 12/18/2024","primary_completion_date":" 12/18/2024","study_txt":" Completion: 12/18/2024","study_completion_date":" 12/18/2024","last_update_posted":"2025-02-13"},{"id":"6858793b-66b6-4bd1-8de9-e5db913af128","acronym":"","url":"https://clinicaltrials.gov/study/NCT03533582","created_at":"2021-01-18T17:24:25.522Z","updated_at":"2025-02-25T15:10:48.947Z","phase":"Phase 3","brief_title":"Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery","source_id_and_acronym":"NCT03533582","lead_sponsor":"Children's Oncology Group","biomarkers":" SMARCB1 • AFP","pipe":" | ","alterations":" AFP elevation","tags":["SMARCB1 • AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • gemcitabine • sorafenib • 5-fluorouracil • doxorubicin hydrochloride • oxaliplatin • etoposide IV • irinotecan • vincristine • daunorubicin • fluorouracil topical"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 537","initiation":"Initiation: 05/24/2018","start_date":" 05/24/2018","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-13"}]